REG - BSF Enterprise PLC - Supply Agreement with SeaWith

BSF EnterpriseAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260319:nRSS2085Xa&default-theme=true

RNS Number : 2085X  BSF Enterprise PLC  19 March 2026

19 March 2026

 

BSF Enterprise PLC

 

3D Bio-Tissues Limited ("3DBT")

Signs Commercial Supply Agreement with SeaWith

BSF Enterprise PLC (LSE: BSFA) (the "Company"), a leading innovator in
tissue-engineered materials, is pleased to announce that its subsidiary, 3D
Bio-Tissues Limited ("3DBT"), has entered into a five-year commercial Supply
Agreement (the "Agreement") with SeaWith, a pioneering South Korean
biotechnology company specializing in cultivated meat.

 

Strategic Partnership and Value Creation

 

The Agreement establishes a long-term commercial framework for the supply of
3DBT's proprietary City-Mix®, a premium macromolecular crowder designed to
enhance cell culture efficiency. This partnership represents a significant
milestone in expanding the market reach of City-Mix® into the global
cultivated protein sector.

 

·      Contract Value: The total value of the Agreement to 3DBT is
estimated at approximately £300,000 over the contract term.

·      Operational Integration: 3DBT will provide a regular supply of
City-Mix® to support SeaWith's production pipeline for its flagship
Welldone™ cultivated beef product.

·      Cost Efficiency: City-Mix® is expected to significantly lower
production costs for SeaWith by reducing the requirement for expensive growth
media by approximately 30%.

·      Growth Trajectory: The Agreement supports a phased scale-up of
supply volumes through 2030, aligning with SeaWith's transition toward
large-scale commercial production facilities.

 

About SeaWith

Founded in 2019 and headquartered in South Korea, SeaWith is a biotechnology
innovator that has raised over $8 million in venture funding to date. The
company utilizes seaweed-derived technologies to produce sustainable,
slaughter-free meat alternatives, focusing on scalability and the reduction of
environmental impact. SeaWith is a designated operator under South Korea's
Gyeongbuk Cell-Cultured Food Regulatory Free Zone, reflecting the company's
leadership in advancing cultivated food innovation within a
government-supported regulatory framework.

 

END

 

Engage with the BSF Enterprise management team directly by asking questions,
watching video
summaries and seeing what other shareholders have to say. Navigate to our
Interactive Investor
website here:

 

https://bsfenterprise.com/link/Pqnkoy (https://bsfenterprise.com/link/Pqnkoy)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 

 BSF Enterprise PLC                                                           https://bsfenterprise.com/s/a1f22b (https://bsfenterprise.com/s/a1f22b)

 Geoff Baker - Chairman

 Che Connon - CEO & Director

 We encourage all investors to share questions on this announcement via our
 investor website.
 Shard Capital (Broker)

 Damon Heath                                                                  (0)20 4530 6926

 Isabella Pierre                                                              (0)20 4530 6928
 ISIN of the Ordinary Shares

 is GB00BHNBDQ51.

 SEDOL Code is BHNBDQ5.

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43
(https://bsfenterprise.com/s/bb9f43)

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather (via LGL), cultivated
meat, and corneal repair technologies. By leveraging its proprietary
scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance
alternatives to conventional materials, targeting global markets where
provenance, ethics, and performance are increasingly prized by consumers and
brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRMZGMFNRDGVZM



            Copyright 2019 Regulatory News Service, all rights reserved